1887

Abstract

The Epstein–Barr virus (EBV) is a ubiquitous pathogen that infects over 90 % of adults. EBV is the primary etiological agent of infectious mononucleosis and is closely associated with nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma and Burkitt lymphoma. Clinical serological assays for EBV diagnosis only survey a small portion of the viral proteome, which does not represent the total antigenic breadth presented to the immune system during viral infection. In this study, we have generated an expression library containing the majority of EBV ORFs, and have systematically evaluated IgG responses to those EBV proteins in sera from EBV carriers. In addition to confirming previously recognized dominant EBV antigens, this study has identified additional immunodominant antigens, and has revealed a more expansive antigenic profile of the humoral responses to EBV in asymptomatic carriers. This EBV expression library will be deposited in a public repository with the goal of disseminating this new research tool for the application of identifying potential new biomarkers for EBV-associated diseases.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000891
2017-09-01
2020-01-26
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/9/2343.html?itemId=/content/journal/jgv/10.1099/jgv.0.000891&mimeType=html&fmt=ahah

References

  1. Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer 2016;16:789–802 [CrossRef][PubMed]
    [Google Scholar]
  2. Basson V, Sharp AA. Monospot: a differential slide test for infectious mononucleosis. J Clin Pathol 1969;22:324–325 [CrossRef][PubMed]
    [Google Scholar]
  3. Tetrault G. Infections in heterophile-negative patients. Arch Pathol Lab Med 2001;125:858–859 [CrossRef][PubMed]
    [Google Scholar]
  4. Bruu AL, Hjetland R, Holter E, Mortensen L, Natås O et al. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin Diagn Lab Immunol 2000;7:451–456 [CrossRef][PubMed]
    [Google Scholar]
  5. De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J Virol 2012;1:31–43 [CrossRef][PubMed]
    [Google Scholar]
  6. Bauer G. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin Lab 2001;47:223–230[PubMed]
    [Google Scholar]
  7. Middeldorp JM, Herbrink P. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J Virol Methods 1988;21:133–146 [CrossRef][PubMed]
    [Google Scholar]
  8. Milman G, Scott AL, Cho MS, Hartman SC, Ades DK et al. Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man. Proc Natl Acad Sci USA 1985;82:6300–6304 [CrossRef][PubMed]
    [Google Scholar]
  9. van Grunsven WM, Nabbe A, Middeldorp JM. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J Med Virol 1993;40:161–169 [CrossRef][PubMed]
    [Google Scholar]
  10. van Grunsven WM, Spaan WJ, Middeldorp JM. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J Infect Dis 1994;170:13–19 [CrossRef][PubMed]
    [Google Scholar]
  11. van Grunsven WM, van Heerde EC, de Haard HJ, Spaan WJ, Middeldorp JM. Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins. J Virol 1993;67:3908–3916[PubMed]
    [Google Scholar]
  12. Henle W, Henle GE, Horwitz CA. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 1974;5:551–565 [CrossRef][PubMed]
    [Google Scholar]
  13. Gärtner BC, Hess RD, Bandt D, Kruse A, Rethwilm A et al. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diagn Lab Immunol 2003;10:78–82 [CrossRef][PubMed]
    [Google Scholar]
  14. Rowe M, Finke J, Szigeti R, Klein G. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol 1988;69:1217–1228 [CrossRef][PubMed]
    [Google Scholar]
  15. Houali K, Wang X, Shimizu Y, Djennaoui D, Nicholls J et al. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res 2007;13:4993–5000 [CrossRef][PubMed]
    [Google Scholar]
  16. Feng P, Chan SH, Soo MY, Liu D, Guan M et al. Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis. Cancer 2001;92:1872–1880[PubMed][CrossRef]
    [Google Scholar]
  17. Xiao J, Palefsky JM, Herrera R, Sunshine C, Tugizov SM. EBV-positive human sera contain antibodies against the EBV BMRF-2 protein. Virology 2009;393:151–159 [CrossRef][PubMed]
    [Google Scholar]
  18. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A et al. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 2004;190:53–62 [CrossRef][PubMed]
    [Google Scholar]
  19. Hinderer W, Lang D, Rothe M, Vornhagen R, Sonneborn HH et al. Serodiagnosis of Epstein-Barr virus infection by using recombinant viral capsid antigen fragments and autologous gene fusion. J Clin Microbiol 1999;37:3239–3244[PubMed]
    [Google Scholar]
  20. Yao QY, Rowe M, Martin B, Young LS, Rickinson AB. The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. J Gen Virol 1991;72:1579–1590 [CrossRef][PubMed]
    [Google Scholar]
  21. Zheng D, Wan J, Cho YG, Wang L, Chiou CJ et al. Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray. J Infect Dis 2011;204:1683–1691 [CrossRef][PubMed]
    [Google Scholar]
  22. Emini EA, Schleif WA, Armstrong ME, Silberklang M, Schultz LD et al. Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine. Virology 1988;166:387–393 [CrossRef][PubMed]
    [Google Scholar]
  23. Labo N, Miley W, Marshall V, Gillette W, Esposito D et al. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog 2014;10:e1004046 [CrossRef][PubMed]
    [Google Scholar]
  24. Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 1984;33:27–32 [CrossRef][PubMed]
    [Google Scholar]
  25. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008;10:279–292 [CrossRef][PubMed]
    [Google Scholar]
  26. Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H et al. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol 2003;41:5419–5428 [CrossRef][PubMed]
    [Google Scholar]
  27. Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol 2015;33:787–821 [CrossRef][PubMed]
    [Google Scholar]
  28. Vroman B, Luka J, Rodriguez M, Pearson GR. Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus. J Virol 1985;53:107–113[PubMed]
    [Google Scholar]
  29. Middeldorp JM, Meloen RH. Epitope-mapping on the Epstein-Barr virus major capsid protein using systematic synthesis of overlapping oligopeptides. J Virol Methods 1988;21:147–159 [CrossRef][PubMed]
    [Google Scholar]
  30. Kishishita M, Luka J, Vroman B, Poduslo JF, Pearson GR. Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen. Virology 1984;133:363–375 [CrossRef][PubMed]
    [Google Scholar]
  31. Middeldorp JM. Epstein-Barr virus-specific humoral immune responses in health and disease. Curr Top Microbiol Immunol 2015;391:289–323 [CrossRef][PubMed]
    [Google Scholar]
  32. Zeng Y, Middeldorp J, Madjar JJ, Ooka T. A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 1997;239:285–295 [CrossRef][PubMed]
    [Google Scholar]
  33. Daikoku T, Kudoh A, Fujita M, Sugaya Y, Isomura H et al. Architecture of replication compartments formed during Epstein-Barr virus lytic replication. J Virol 2005;79:3409–3418 [CrossRef][PubMed]
    [Google Scholar]
  34. Cho MS, Milman G, Hayward SD. A second Epstein-Barr virus early antigen gene in BamHI fragment M encodes a 48- to 50-kilodalton nuclear protein. J Virol 1985;56:860–866[PubMed]
    [Google Scholar]
  35. Luka J, Miller G, Jörnvall H, Pearson GR. Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein. J Virol 1986;58:748–756[PubMed]
    [Google Scholar]
  36. Glaser R, Boyd A, Stoerker J, Holliday J. Functional mapping of the Epstein-Barr virus genome: identification of sites coding for the restricted early antigen, the diffuse early antigen, and the nuclear antigen. Virology 1983;129:188–198 [CrossRef][PubMed]
    [Google Scholar]
  37. Wong KM, Levine AJ. Characterization of proteins encoded by the Epstein-Barr virus transactivator gene BMLF1. Virology 1989;168:101–111 [CrossRef][PubMed]
    [Google Scholar]
  38. de Sanjosé S, Bosch R, Schouten T, Verkuijlen S, Nieters A et al. Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. Int J Cancer 2007;121:1806–1812 [CrossRef][PubMed]
    [Google Scholar]
  39. Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A et al. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J Infect Dis 1999;179:1108–1115 [CrossRef][PubMed]
    [Google Scholar]
  40. Lennette ET, Winberg G, Yadav M, Enblad G, Klein G. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer 1995;31A:1875–1878 [CrossRef][PubMed]
    [Google Scholar]
  41. Paramita DK, Fatmawati C, Juwana H, van Schaijk FG, Fachiroh J et al. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls. J Med Virol 2011;83:665–678 [CrossRef][PubMed]
    [Google Scholar]
  42. Meij P, Vervoort MB, Bloemena E, Schouten TE, Schwartz C et al. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J Med Virol 2002;68:370–377 [CrossRef][PubMed]
    [Google Scholar]
  43. Ben-Bassat H, Goldblum N, Mitrani S, Goldblum T, Yoffey JM et al. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer 1977;19:27–33 [CrossRef][PubMed]
    [Google Scholar]
  44. Menezes J, Leibold W, Klein G, Clements G. Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 1975;22:276–284[PubMed]
    [Google Scholar]
  45. Takada K, Horinouchi K, Ono Y, Aya T, Osato T et al. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 1991;5:147–156 [CrossRef][PubMed]
    [Google Scholar]
  46. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685 [CrossRef][PubMed]
    [Google Scholar]
  47. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671–675 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000891
Loading
/content/journal/jgv/10.1099/jgv.0.000891
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error